Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06895967 · ClinicalTrials.gov registry record · Phase 1
A Study of TAK-881 and HyQvia in Healthy Adults
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT06895967 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 30 participants.
The verdict
NCT06895967, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The main aim of this study is to understand how the body absorbs, processes, and removes (known as pharmacokinetics or PK) TAK-881 and HyQvia, after they are given as a single injection under the skin in healthy adults. Study participants will receive a single dose of TAK-881 or HyQvia on Day 1. During the study, participants will need to stay at the clinic for 8 days followed by 8 ambulatory follow up visits till Day 85.
Interventions
- BIOLOGICAL TAK-881
- DEVICE SC Investigational Needle Sets
- BIOLOGICAL HyQvia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-03-24 |
| Est. Completion | 2025-08-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06895967
The ClinicalTrials.gov registry entry for NCT06895967 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which TAK-881 is the first listed.
NCT06895967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06895967 about?
NCT06895967 is a clinical study titled "A Study of TAK-881 and HyQvia in Healthy Adults". The main aim of this study is to understand how the body absorbs, processes, and removes (known as pharmacokinetics or PK) TAK-881 and HyQvia, after they are given as a single injection under the skin in healthy adults. Study participants will receive a single dose of TAK-881 or HyQvia on Day 1. D...
What is the current status of trial NCT06895967?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-03-24. Estimated completion is 2025-08-08.
What interventions are being tested in trial NCT06895967?
The interventions under investigation include: TAK-881 (BIOLOGICAL), SC Investigational Needle Sets (DEVICE), HyQvia (BIOLOGICAL).
Who is sponsoring clinical trial NCT06895967?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.